18.2亿收购！2025疼痛市场真的要“变天”了？
前日（2月7日）， 全球骨科手术机器人龙头企业Globus Medical（NYSE: GMED）宣布以每股5.85美元的价格收购慢性疼痛治疗公司Nevro（NYSE: NVRO）全部股份，总股权价值达2.5亿美元（约合18.2亿元人民币） 。这一价格较Nevro过去90天的平均股价溢价27%，较30天平均股价溢价38%，交易预计于2025年第二季度末完成。
来自MSN1 天
Piper Sandler Upgrades Nevro (NVRO)
Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to ...
marketinference1 天
Globus Medical Acquires Nevro Corp for $250M
Globus Medical, a leading musculoskeletal solutions company, has announced its acquisition of Nevro Corp, a global medical ...
Nevro upgraded to Hold from Underperform at Jefferies
Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...
Nevro (NVRO) Upgraded to Buy: What Does It Mean for the Stock?
Nevro (NVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MassDevice2 天
Globus Medical to acquire Nevro for $250M
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Nevro price target raised to $5.85 from $4 at Canaccord
Canaccord raised the firm’s price target on Nevro (NVRO) to $5.85 from $4 and keeps a Hold rating on the shares. The firm noted Globus Medical ...
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Piper Sandler raises Nevro stock to Neutral, cuts target to $5.85
Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market ...
Piper Sandler上调Nevro评级至中性，目标价下调至5.85美元
周五，Piper Sandler分析师Adam Maeder将市值2.14亿美元的医疗设备公司Nevro Corp (NYSE: NVRO )的股票评级从减持上调至中性，并将目标价从6.00美元下调至5.85美元。此次调整是在Nevro宣布与Globus Medical Inc. (NYSE: GMED )达成最终收购协议后做出的，后者将以每股5.85美元的现金价格收购Nevro。